Baidu
map

JAMA Intern Med:75-79岁老年糖尿病患者胰岛素使用与停药率

2019-09-24 MedSci MedSci原创

研究发现,对于患有II型糖尿病的老年患者,其自身健康状态与胰岛素的使用率相关,部分健康状态良好人群在75岁以后可停止胰岛素使用

近日,研究人员考察了健康状况不佳的老年人与健康状况良好的老年人相比,胰岛素治疗的使用频率和停药频率差异。

21531名II型糖尿病患者,从75岁开始,随访时间长达4年。健康状况被定义为良好(<2种共患病或2种共患病但可进行体力活动)、中度(>2种共患病或2种共患病且自我报告未进行每周锻炼),或不良(有终末期肺、心脏或肾脏疾病,痴呆诊断或转移性癌症)。研究的主要终点为胰岛素使用率及停药率。

21531例患者中,女性10396例(48.3%),平均年龄75岁,近五分之一(4076人[18.9%])使用胰岛素。与健康状态良好人群相比,不良及中等人群,75岁胰岛素使用风险增加(aRR,2.03和1.85)。32.7%的胰岛素使用者在入组后4年内停止使用胰岛素。健康状况不良(aRR 1.47)和中等(aRR 1.16)个体继续使用胰岛素的可能性更高。

研究发现,对于患有II型糖尿病的老年患者,其自身健康状态与胰岛素的使用率相关,部分健康状态良好人群在75岁以后可停止胰岛素使用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1750100, encodeId=54301e5010076, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Aug 07 15:33:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460841, encodeId=dfde146084105, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474822, encodeId=da6014e482253, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479541, encodeId=8f4f14e9541f6, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609991, encodeId=25ba160999101, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042729, encodeId=12bd1042e290f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Sep 24 20:33:00 CST 2019, time=2019-09-24, status=1, ipAttribution=)]
    2020-08-07 baoya
  2. [GetPortalCommentsPageByObjectIdResponse(id=1750100, encodeId=54301e5010076, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Aug 07 15:33:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460841, encodeId=dfde146084105, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474822, encodeId=da6014e482253, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479541, encodeId=8f4f14e9541f6, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609991, encodeId=25ba160999101, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042729, encodeId=12bd1042e290f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Sep 24 20:33:00 CST 2019, time=2019-09-24, status=1, ipAttribution=)]
    2019-09-26 yinhl1980
  3. [GetPortalCommentsPageByObjectIdResponse(id=1750100, encodeId=54301e5010076, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Aug 07 15:33:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460841, encodeId=dfde146084105, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474822, encodeId=da6014e482253, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479541, encodeId=8f4f14e9541f6, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609991, encodeId=25ba160999101, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042729, encodeId=12bd1042e290f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Sep 24 20:33:00 CST 2019, time=2019-09-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1750100, encodeId=54301e5010076, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Aug 07 15:33:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460841, encodeId=dfde146084105, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474822, encodeId=da6014e482253, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479541, encodeId=8f4f14e9541f6, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609991, encodeId=25ba160999101, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042729, encodeId=12bd1042e290f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Sep 24 20:33:00 CST 2019, time=2019-09-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1750100, encodeId=54301e5010076, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Aug 07 15:33:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460841, encodeId=dfde146084105, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474822, encodeId=da6014e482253, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479541, encodeId=8f4f14e9541f6, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609991, encodeId=25ba160999101, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042729, encodeId=12bd1042e290f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Sep 24 20:33:00 CST 2019, time=2019-09-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1750100, encodeId=54301e5010076, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Aug 07 15:33:00 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460841, encodeId=dfde146084105, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474822, encodeId=da6014e482253, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479541, encodeId=8f4f14e9541f6, content=<a href='/topic/show?id=466b8021e01' target=_blank style='color:#2F92EE;'>#老年糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80217, encryptionId=466b8021e01, topicName=老年糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609991, encodeId=25ba160999101, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 26 08:33:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042729, encodeId=12bd1042e290f, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Sep 24 20:33:00 CST 2019, time=2019-09-24, status=1, ipAttribution=)]
    2019-09-24 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Circulation:二甲双胍与有无心衰/肾功能不全的糖尿病患者预后的相关性

二甲双胍是治疗2型糖尿病的一线药物,但其对心血管系统的作用尚未得到证实。研究人员对SAVOR-TIMI 53试验(沙格列汀与2型糖尿病患者的心血管预后)的患者(12156位)进行二次分析,评估二甲双胍暴露与预后的相关性。在12156位患者中,8971位(74%)有二甲双胍暴露,1611位(13%)有心衰史,1332位(11%)至少有中度的慢性肾病(估计肾小球滤过率≤45 mL·min?1·1.73

JAMA:Linagliptin可改善早期糖尿病患者心血管事件风险

研究认为,在早期II型糖尿病伴心血管风险升高的成年人中,linagliptin可降低患者的心血管结局风险,效果与格列美脲相当

JAMA :二甲双胍对肾功能减退的糖尿病患者安全性良好

研究发现,在坚持单药治疗的糖尿病伴肾功能下降患者中,二甲双胍治疗与磺脲类药物相比,MACE风险更低

Clinica Chimica Acta:马丁方程对埃及2型糖尿病患者LDL-C估计的评价

2型糖尿病具有特征性血脂异常。低密度脂蛋白胆固醇(LDL-C)测量在心血管风险评估和管理中发挥着重要作用。而弗里德瓦尔德方程(FE)有几个局限性。本研究旨在评估马丁方程(ME)在埃及患者,尤其是2型糖尿病患者中的有效性。

EASD2019:用健康饮食武装糖尿病管理

与西方不同,在中国常能听到“早餐要吃好,午餐要吃饱,晚餐要吃少”。这句我们挂在嘴边的俗语看似普通,实则饱含经岁月沉淀的智慧。正在巴塞罗那进行的欧洲糖尿病研究协会(EASD)年会就专门设置了饮食的话题——三餐比例的分配、饮食结构的蛋白质氨基酸组成都对糖尿病管理有着不可忽视的影响。

EASD2019:大脑是糖尿病和肥胖的元凶还是受害者?

众所周知,肥胖是痴呆及临床阿尔茨海默病(AD)的危险因素,还有很多糖尿病患者存在认知功能障碍。既往研究发现,体重指数(BMI)与大脑皮质萎缩之间存在相关性。那么,肥胖到底会导致哪些脑代谢及结构变化?1型及2型糖尿病到底与认知功能之间存在着怎么的密切关系?炎症生物标志物在其中又发挥了怎样的作用?来自EASD会场的最新研究结果能否让您对这些疑问有新的认识呢?

Baidu
map
Baidu
map
Baidu
map